Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study hopes to unlock secrets of rare brain condition in children

NCT ID NCT07421219

Knowledge-focused Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This observational study will follow 50 children aged 5 to 8 with non-progressive congenital ataxia, a rare condition that affects movement and coordination. Researchers will use detailed exams, brain scans, and genetic testing to better understand the disorder and its impact on quality of life. The goal is to improve diagnosis and pave the way for future targeted treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lead to better diagnostic tools and targeted therapies for children with non-progressive congenital ataxia.
What could go wrong
This is an observational study, not a treatment trial, so no direct benefit to participants. It is small (50 children) and early-stage, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children, aged 5 to 8 years at time of data collection, with a confirmed diagnosis of NPCA/ataxic CP (according to SCPE criteria), will be identified through university hospitals, regional hospitals, outpatient neurology / rehabilitation clinics, and CP registries, in eight European participating countries (France, Belgium, Denmark, Germany, Greece, Norway, Hungary and Sweden). Recruitment will take place during routine follow-up or planned clinical visits.

Ages

5 to 8 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • male or female children * confirmed diagnosis of NPCA/Ataxic CP (SCPE definition) * aged ≥ 5 years and ≤ 8 years at time of data collection * written informed consent of at least one parent or legal representative in accordance to country regulations, and verbal assent of the child when possible Exclusion Criteria: Children with all other diagnoses of movement disorders or other CP subtypes \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ataxic cerebral palsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ataxic cerebral palsy Cerebral Palsy, Ataxic, Autosomal Recessive neurodevelopmental disorder spinocerebellar ataxia type 29

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ataxic cerebral palsy Non-progressive congenital ataxia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    NOT_YET_RECRUITING

    Aarhus, Denmark

  • IASO Children's Hospital

    NOT_YET_RECRUITING

    Athens, Greece

  • KU Leuven

    NOT_YET_RECRUITING

    Leuven, Belgium

  • Queen Silvia Children's Hospital at Sahlgrenska University Hospital

    RECRUITING

    Gothenburg, 416 50, Sweden

  • Toulouse University Hospital

    NOT_YET_RECRUITING

    Toulouse, France

  • University Hospital Tübingen

    RECRUITING

    Tübingen, Germany

  • Vestfold Hospital Trust

    NOT_YET_RECRUITING

    Tønsberg, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.